The stock of Cytosorbents Corp (NASDAQ: CTSO) has decreased by -22.48% when compared to last closing price of $1.29. Despite this, the company has experienced a -16.67% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-02 that PRINCETON, N.J., July 2, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada.
Is It Worth Investing in Cytosorbents Corp (NASDAQ: CTSO) Right Now?
The stock has a 36-month beta value of 1.22. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CTSO is 51.94M, and at present, short sellers hold a 2.76% of that float. On July 03, 2025, the average trading volume of CTSO was 109.82K shares.
CTSO’s Market Performance
The stock of Cytosorbents Corp (CTSO) has seen a -16.67% decrease in the past week, with a 16.55% rise in the past month, and a 0.00% fall in the past quarter. The volatility ratio for the week is 8.73%, and the volatility levels for the past 30 days are at 9.84% for CTSO. The simple moving average for the last 20 days is -12.66% for CTSO stock, with a simple moving average of -3.49% for the last 200 days.
Analysts’ Opinion of CTSO
Many brokerage firms have already submitted their reports for CTSO stocks, with B. Riley Securities repeating the rating for CTSO by listing it as a “Buy.” The predicted price for CTSO in the upcoming period, according to B. Riley Securities is $4 based on the research report published on September 07, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CTSO reach a price target of $10. The rating they have provided for CTSO stocks is “Buy” according to the report published on October 14th, 2021.
Jefferies gave a rating of “Buy” to CTSO, setting the target price at $15 in the report published on September 17th of the previous year.
CTSO Trading at -1.26% from the 50-Day Moving Average
After a stumble in the market that brought CTSO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTSO starting from MARIANI PETER J, who purchase 20,000 shares at the price of $0.96 back on Dec 13 ’24. After this action, MARIANI PETER J now owns 401,363 shares of Cytosorbents Corp, valued at $19,294 using the latest closing price.
MARIANI PETER J, the Chief Financial Officer of Cytosorbents Corp, purchase 20,000 shares at $0.89 during a trade that took place back on Dec 12 ’24, which means that MARIANI PETER J is holding 381,363 shares at $17,872 based on the most recent closing price.
Stock Fundamentals for CTSO
Current profitability levels for the company are sitting at:
- -0.56 for the present operating margin
- 0.96 for the gross margin
The net margin for Cytosorbents Corp stands at -0.57. The total capital return value is set at -0.38. Equity return is now at value -94.65, with -32.37 for asset returns.
Based on Cytosorbents Corp (CTSO), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.53. The debt to equity ratio resting at 1.85. The interest coverage ratio of the stock is -19.77.
Currently, EBITDA for the company is -19.26 million with net debt to EBITDA at -0.8. When we switch over and look at the enterprise to sales, we see a ratio of 2.82. The receivables turnover for the company is 3.61for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.61.
Conclusion
To sum up, Cytosorbents Corp (CTSO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
